Presented on March 22nd, 2021 | Duration: 49m 51s
Viral diversity presents an ongoing challenge for diagnostic tests, which must be designed to accurately detect all current and future circulating strains. This webinar aims to help better understand viral diversity and the impact it has on diagnostic tools, explore the current state of SARS-CoV-2 surveillance, and discuss how to stay ahead of the next pandemic with Abbott’s Pandemic Defense Coalition.

Presented on July 1st, 2020 | Duration: 1h
Exchanging views on the role and contributions of polyvalent, high throughput molecular platforms in early case finding and prompt treatment of TB and DR-TB.

Presented on July 8th, 2020 | Duration: 1h 14m
Discusses design and development of the SARS CoV-2 diagnostic assay as well as a review of different strategies on the implementation of SARS-CoV-2 molecular testing under FDA Emergency Use Authorization only (EUA) in a US Integrated Hospital Delivery Network (IDN).

Presented on August 18th, 2020 | Duration: 55m
Understanding how Alinity m meets the 2009 international consensus guidelines on test requirements for primary cervical cancer screening, demonstrating performance characteristics of the Alinity m HR HPV assay in the VALGENT-3 framework and assessing the importance of extended genotyping to evaluate risk and triage patients effectively.

Presented on July 29th, 2020 | Duration: 1h 2m
Hepatitis C infection, once a formidable enemy, is now a curable disease. Unfortunately, many individuals today who are infected with hepatitis C are completely unaware of infection status. Bridging the gap between unaware and diagnosed can make huge differences in a patient’s long-term prognosis.

Presented on October 28th, 2020 | Duration: 1h 3m
The new In Vitro Diagnostic Regulation (IVDR) has been defined as one of the most significant changes in the EU legislation for In Vitro Diagnostics in the past 20 years. This webinar will be part of a series that Abbott will be providing, with the end goal of supporting molecular laboratories during this important transition.

Presented on September 8th, 2020 | Duration: 46m
Reviews the available molecular methodologies for identifying gene rearrangements specifically focusing on ALK and ROS1 gene rearrangement testing in non-small cell lung cancer, including overview of the technology, the current recommendations, common practices and challenges associated with these methodologies.

Presented on March 10, 2023 | Duration: 65m
The speakers discuss the epidemiology, screening and diagnostic testing recommendations, and current treatments for Trichomonas vaginalis and Mycoplasma genitalium.